Retatrutide for Weight Loss and Type 2 Diabetes Research
Retatrutide is a cutting-edge investigational drug being studied for its potential in weight management and type 2 diabetes treatment. It’s a triple hormone receptor agonist, targeting GLP-1, GIP, and glucagon receptors, which may help regulate appetite, blood sugar, and energy expenditure.
Unlike traditional GLP-1 agonists, retatrutide’s triple action makes it a promising candidate for even greater metabolic benefits. It is not yet FDA-approved and is available for research purposes only.
Key Research Findings
-
May reduce HbA1c by up to 2.5% in type 2 diabetes patients
-
Reported weight loss over 24% in clinical trials (among the highest to date)
-
Designed to improve glucose control, fat metabolism, and satiety
This information is for research and educational purposes only. It is not intended as a medical recommendation or claim. Always consult a healthcare provider for medical advice.
The retatrutide sold here is for research use only and is not for human consumption.
Retatrutide Dosing (Research Use Only)
Research protocols commonly use the following dosing pattern:
-
Starting dose: 2 mg weekly via subcutaneous injection
-
Dose escalation: Increases by 2 mg every 4 weeks, up to 12 mg weekly, depending on tolerance and research goals
-
Injection sites: Stomach, thigh, or upper arm (rotate sites regularly)
-
Form: Usually supplied as injectable solution for research labs
Retatrutide Side Effects – Clinical Data Summary
| Side Effect | Approximate Incidence | Notes |
|---|---|---|
| Nausea | 25–50% | More common at higher doses (≥8 mg); usually transient |
| Diarrhea | 15–30% | Mild to moderate; dose-dependent |
| Constipation | 10–20% | Similar to other GLP-1s; often manageable |
| Vomiting | 5–15% | Often resolves with continued use |
| Decreased appetite | 30–50% | Major contributor to weight reduction |
| Fatigue | ~10% | Mild and self-limiting |
| Hair thinning/loss | ~5–7% | Observed in weight-loss trials (likely due to rapid weight change) |
| Gallbladder issues | ~1–2% | Risk of gallstones or cholecystitis |
| Pancreatitis (rare) | <1% | Serious but uncommon risk (similar to GLP-1 drugs) |
Data from Phase 2 clinical trials; subject to change as further studies progress. This table is not exhaustive and is for informational use only.
Disclaimer
Retatrutide is sold strictly for research use only and is not approved for human use. All content above is for informational and educational purposes. It does not constitute medical advice or treatment guidance.
Reviews
There are no reviews yet.